EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genomic Alterations of Tumors in HER2-Low Breast Cancers

Yi-Fang Tsai, Chi-Cheng Huang iD, Chih-Yi Hsu iD, Chin-Jung Feng, Yen-Shu Lin, Ta-Chung Chao, Jiun-I Lai, Pei-Ju Lien, Chun-Yu Liu, Jen-Hwey Chiu iD, Ling-Ming Tseng

International Journal of Molecular Sciences · 21.01.2024 · 25 (2) · 1318

DOI: 10.3390/ijms25021318 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 21.01.2024. Verfasst von Yi-Fang Tsai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei 112201, Taiwan. Hauptthemen laut MEDLINE: Breast Neoplasms, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Melissa Lee cancer fundation, Taipei Veterans General Hospital, Taiwan, Taipei Veterans General Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study was to elucidate molecular profiling in HER2-low tumors based on a promising dataset. A total of 615 consecutive HER2-negative breast cancer samples were assayed. The genomic mutations in the two groups with different HER2 expression levels (HER2-0 vs. HER2-low) were compared. The mutation types obtained via next-generation targeted sequencing were correlated with the clinicopathological features of the patients with HER2-0 and HER2-low breast cancer. The results showed that there was a significantly higher percentage of receptor-positive (ER/PR) tumors and more low-level Ki-67 tumors, but a lower incidence of stage I/II tumors in the HER2-low group compared to the HER2-0 group. There was a significantly higher frequency of 17.62% (65/369) for PIK3CA_SNA in the HER2-low group than in the HER2-0 group, which had a frequency of only 9.35% (23/246) (p = 0.006). When the called gene alterations in the triple-negative breast cancer (TNBC) group were compared with those in the luminal-like breast cancer group, there was a significantly high frequency of 28.17% (140/497) for ERBB2_SNA in a luminal-like group than in the TNBC group(16.95% (20/118)).We conclude that the early detection of PIK3CA mutations is likely to be important and might help therapeutic decision making in patients with HER2-low tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTriple Negative Breast NeoplasmsFemaleHumansBiomarkers, TumorGenomicsMutationErb-b2 Receptor Tyrosine KinasesReceptors, Progesterone

Stichwörter der Autor:innen

HER2-low carcinomabreast cancerhuman epidermal growth factor receptor-2next-generation sequencing

Substanzen

Biomarkers, TumorErb-b2 Receptor Tyrosine KinasesReceptors, Progesterone

Autor:innen und Institutionen

  • Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei 112201, Taiwan.
  • Division of Breast Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei 112201, Taiwan.
  • Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112201, Taiwan.
  • School of Public Health, College of Public Health, National Taiwan University, Taipei 112201, Taiwan.
  • Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei 112201, Taiwan.
  • College of Nursing, National Taipei University of Nursing and Health Sciences, Taipei 112201, Taiwan.

ORCID-Profile: Chi-Cheng Huang, Chih-Yi Hsu, Jen-Hwey Chiu

Förderung

  • The Melissa Lee cancer fundation
  • Taipei Veterans General Hospital, Taiwan
  • Taipei Veterans General Hospital
  • Melissa Lee Cancer Foundation

Zitieren

APA

Tsai, Y. F., Huang, C. C., Hsu, C. Y., Feng, C. J., Lin, Y. S., Chao, T. C., Lai, J. I., Lien, P. J., Liu, C. Y., Chiu, J. H., & Tseng, L. M. (2024). Genomic Alterations of Tumors in HER2-Low Breast Cancers. International Journal of Molecular Sciences, 25(2), 1318. https://doi.org/10.3390/ijms25021318

Vancouver

Tsai YF, Huang CC, Hsu CY, Feng CJ, Lin YS, Chao TC, et al. Genomic Alterations of Tumors in HER2-Low Breast Cancers. International Journal of Molecular Sciences. 2024;25(2):1318. doi:10.3390/ijms25021318

BibTeX
@article{Tsai2024,
  author = {Tsai, Yi-Fang and Huang, Chi-Cheng and Hsu, Chih-Yi and Feng, Chin-Jung and Lin, Yen-Shu and Chao, Ta-Chung and Lai, Jiun-I and Lien, Pei-Ju and Liu, Chun-Yu and Chiu, Jen-Hwey and Tseng, Ling-Ming},
  title = {Genomic Alterations of Tumors in HER2-Low Breast Cancers},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {2},
  pages = {1318},
  doi = {10.3390/ijms25021318}
}
Kostenlos starten →